Arts

Books

Fashion & Beauty

Performing Arts

Food

Visual Arts

Design

Business

Entrepreneurship

Investing

Marketing

Careers

Management

Non-Profit

Comedy

Stand-Up

Comedy Interviews

Improv

Education

Self-Improvement

How To

Courses

Language Learning

Fiction

Comedy Fiction

Drama

Science Fiction

Government

Health & Fitness

Medicine

Alternative Health

Nutrition

Mental Health

Fitness

Sexuality

History

Kids & Family

Parenting

Stories for Kids

Education for Kids

Pets & Animals

Leisure

Video Games

Games

Automotive

Animation & Manga

Hobbies

Aviation

Home & Garden

Crafts

Music

Music Commentary

Music Interviews

Music History

News

Sports News

Entertainment News

News Commentary

Politics

Daily News

Business News

Tech News

Religion & Spirituality

Christianity

Spirituality

Religion

Judaism

Islam

Buddhism

Hinduism

Science

Social Sciences

Life Sciences

Natural Sciences

Nature

Chemistry

Mathematics

Earth Sciences

Physics

Astronomy

Society & Culture

Documentary

Relationships

Philosophy

Personal Journals

Places & Travel

Sports

Golf

Soccer

Wrestling

Basketball

Football

Fantasy Sports

Baseball

Wilderness

Running

Hockey

Rugby

Cricket

Volleyball

Tennis

Swimming

Technology

True Crime

TV & Film

Film Interviews

TV Reviews

After Shows

Film Reviews

Film History

In the heart of a bustling research lab at Oxford University, Dr. Sarah Johnson peered intently into her microscope. For years, she and her team had been working tirelessly on a project that could change the lives of millions. Their goal? To create a vaccine that could finally put an end to one of humanity's oldest and deadliest foes: malaria. Sarah's journey had begun years earlier when, as a young medical student, she had volunteered in a rural clinic in Burkina Faso. There, she had witnessed firsthand the devastating impact of malaria, particularly on children. The image of a mother cradling her feverish child, helpless against the parasites ravaging the little one's body, had stayed with her ever since. "We're close," Sarah muttered to herself, adjusting the focus on her microscope. "I can feel it." And indeed, they were. After years of painstaking research, countless failures, and glimmers of hope, Sarah and her team had developed a vaccine they called R21/Matrix-M. It was a mouthful of a name, but it held the promise of saving countless lives. Meanwhile, in a small village in Ghana, Kwame sat outside his home, swatting at mosquitoes in the evening air. His young daughter, Ama, lay inside, her small body wracked with fever. Malaria had struck again, as it did every year when the rains came. Kwame had lost his eldest son to the disease three years ago. Now, as he listened to Ama's labored breathing, he prayed for a miracle. Little did he know that halfway across the world, that miracle was taking shape in the form of a tiny vial of vaccine. Back in Oxford, Sarah's team received the news they had been waiting for. The results from their latest clinical trial were in, and they were nothing short of remarkable. The R21/Matrix-M vaccine had shown an efficacy rate of up to 77% in young children who received a booster dose. "This is it!" Sarah exclaimed, her eyes shining with excitement as she shared the news with her team. "We've done it!" But what exactly had they done? How did this tiny vial of liquid manage to outsmart a parasite that had been outwitting humans for millennia? The secret lay in the vaccine's clever design. It targeted a specific protein found on the surface of the malaria parasite called the circumsporozoite protein, or CSP for short. Think of CSP as the parasite's coat – by teaching the body's immune system to recognize and attack this coat, the vaccine effectively stopped the parasite in its tracks before it could cause harm. But the R21/Matrix-M vaccine had another trick up its sleeve. It included a special ingredient called an adjuvant – Matrix-M. This adjuvant worked like a megaphone for the immune system, amplifying the body's response to the vaccine and making it more effective. As news of the vaccine's success spread, it reached the ears of world leaders and health organizations. In boardrooms and government offices, plans were set in motion to bring this life-saving vaccine to those who needed it most. Ghana, Nigeria, and Burkina Faso were chosen as the first countries to receive the vaccine. For people like Kwame and his daughter Ama, this news brought a glimmer of hope in their ongoing battle against malaria. The logistics of distributing the vaccine were daunting. It required a coordinated effort between local healthcare providers, governments, and international health organizations. But the potential impact was too significant to ignore. Dr. Amina Diallo, a public health official in Burkina Faso, stood before a group of local healthcare workers, explaining the importance of the new vaccine. "This is not just another medicine," she said, her voice filled with passion. "This is our chance to rewrite the story of malaria in our country. Each dose we administer is a step towards a healthier future for our children." The rollout began slowly but steadily. In clinics and hospitals across the selected countries, children lined up to receive their shots. Parents, who had lived in fear of malaria for generations, dared to hope that their children might grow up in a world where the disease was no longer a constant threat. For Kwame and Ama, the vaccine came just in time. As Ama recovered from her bout with malaria, Kwame took her to their local clinic to receive the R21/Matrix-M vaccine. "Will this stop her from getting sick again?" Kwame asked the nurse as she prepared the injection. The nurse smiled gently. "It's not a guarantee," she explained, "but it will give her a much better chance of staying healthy. And with each child we vaccinate, we make our whole community stronger against malaria." As the needle entered Ama's arm, Kwame felt a weight lift from his shoulders. For the first time in years, he allowed himself to imagine a future where he didn't have to fear the coming of the rains and the mosquitoes they brought. Back in Oxford, Sarah and her team were far from resting on their laurels. The success of the R21/Matrix-M vaccine had energized them, spurring them on to even greater endeavors. "We've made a huge step forward," Sarah told her team, "but our work is far from over. There are other strains of malaria out there, other stages in the parasite's lifecycle that we can target. We need to keep pushing, keep innovating." And push they did. In labs around the world, inspired by the success of R21/Matrix-M, researchers redoubled their efforts. They explored new approaches, studied different proteins on the parasite's surface, and looked for ways to make vaccines even more effective. The impact of the R21/Matrix-M vaccine was soon felt across the affected regions. Hospital wards that had once been filled to capacity with malaria patients began to see fewer severe cases. Children who might once have missed school due to recurring bouts of the disease were now able to attend classes regularly. Dr. Diallo, reviewing the latest health statistics for her region, could hardly believe her eyes. "The number of malaria cases has dropped by over 50% in just one year," she announced to her team. "This vaccine is not just saving lives; it's transforming our entire healthcare system." Indeed, as the burden of malaria began to lift, hospitals and clinics found they had more resources to dedicate to other pressing health issues. The ripple effects of the vaccine's success were felt throughout society, from increased productivity as fewer work days were lost to illness, to improved educational outcomes as children spent more time in school. But the fight against malaria was far from over. While the R21/Matrix-M vaccine was a powerful tool, it was not a silver bullet. Mosquito control programs, distribution of bed nets, and other preventive measures remained crucial in the ongoing battle against the disease. Moreover, the parasite that caused malaria was notorious for its ability to adapt and evolve. Scientists knew that they needed to stay one step ahead, continuing to refine and improve their vaccines to maintain their effectiveness. Five years after the initial rollout of the R21/Matrix-M vaccine, Kwame stood proudly at Ama's school graduation ceremony. His daughter, now a healthy teenager, had not suffered a single bout of malaria since receiving the vaccine as a child. As he watched Ama accept her diploma, Kwame's mind wandered back to that fearful night when he had sat outside his home, swatting at mosquitoes and praying for a miracle. The miracle had come, not in the form of divine intervention, but through the dedicated work of scientists like Sarah and her team, and the collaborative efforts of countless individuals around the world. In her lab in Oxford, Sarah Johnson looked at a photo on her desk. It showed her standing with a group of smiling children in Burkina Faso, taken during a recent visit to see the impact of the vaccine firsthand. She picked up the photo, a smile playing on her lips. "We've come so far," she murmured, "but there's still so much to do." And with that, she turned back to her microscope, ready to face the next challenge in the ongoing fight against malaria. For Sarah, Kwame, Ama, and millions of others around the world, the R21/Matrix-M vaccine had turned the tide in humanity's ancient battle against the tiny parasite. It was a reminder of what could be achieved when human ingenuity, scientific rigor, and global cooperation came together to tackle even the most formidable of foes. As the sun set over Oxford and rose over Ghana, the world slept a little easier, knowing that each new day brought them closer to a future free from the scourge of malaria. The mosquito's reign of terror was coming to an end, one vaccine dose at a time. The success of the R21/Matrix-M vaccine had far-reaching implications beyond just the realm of public health. It sparked a renewed interest in tropical disease research, attracting funding and talented scientists to a field that had long been underfunded and overlooked. Governments and philanthropic organizations, seeing the tangible results of their investments, increased their support for similar initiatives targeting other neglected diseases. In universities across the globe, a new generation of students, inspired by the breakthrough, chose to pursue careers in infectious disease research and global health. They saw in Sarah's work a model for how science could make a real, measurable difference in the lives of millions. The vaccine's success also had unexpected economic benefits. As malaria rates dropped, tourism to previously high-risk areas began to increase. Local economies that had long suffered under the shadow of the disease started to flourish. Farmers who had once lost precious workdays to illness found themselves more productive, contributing to improved food security in their regions. But perhaps the most profound impact was on the children. In villages and cities across Africa, a generation was growing up without the constant threat of malaria hanging over them. They attended school more regularly, played outside wit

In the heart of a bustling research lab at Oxford University, Dr. Sarah Johnson peered intently into her microscope. For years, she and her team had been working tirelessly on a project that could change the lives of millions. Their goal? To create a vaccine that could finally put an end to one of humanity's oldest and deadliest foes: malaria. Sarah's journey had begun years earlier when, as a young medical student, she had volunteered in a rural clinic in Burkina Faso. There, she had witnessed firsthand the devastating impact of malaria, particularly on children. The image of a mother cradling her feverish child, helpless against the parasites ravaging the little one's body, had stayed with her ever since. "We're close," Sarah muttered to herself, adjusting the focus on her microscope. "I can feel it." And indeed, they were. After years of painstaking research, countless failures, and glimmers of hope, Sarah and her team had developed a vaccine they called R21/Matrix-M. It was a mouthful of a name, but it held the promise of saving countless lives. Meanwhile, in a small village in Ghana, Kwame sat outside his home, swatting at mosquitoes in the evening air. His young daughter, Ama, lay inside, her small body wracked with fever. Malaria had struck again, as it did every year when the rains came. Kwame had lost his eldest son to the disease three years ago. Now, as he listened to Ama's labored breathing, he prayed for a miracle. Little did he know that halfway across the world, that miracle was taking shape in the form of a tiny vial of vaccine. Back in Oxford, Sarah's team received the news they had been waiting for. The results from their latest clinical trial were in, and they were nothing short of remarkable. The R21/Matrix-M vaccine had shown an efficacy rate of up to 77% in young children who received a booster dose. "This is it!" Sarah exclaimed, her eyes shining with excitement as she shared the news with her team. "We've done it!" But what exactly had they done? How did this tiny vial of liquid manage to outsmart a parasite that had been outwitting humans for millennia? The secret lay in the vaccine's clever design. It targeted a specific protein found on the surface of the malaria parasite called the circumsporozoite protein, or CSP for short. Think of CSP as the parasite's coat – by teaching the body's immune system to recognize and attack this coat, the vaccine effectively stopped the parasite in its tracks before it could cause harm. But the R21/Matrix-M vaccine had another trick up its sleeve. It included a special ingredient called an adjuvant – Matrix-M. This adjuvant worked like a megaphone for the immune system, amplifying the body's response to the vaccine and making it more effective. As news of the vaccine's success spread, it reached the ears of world leaders and health organizations. In boardrooms and government offices, plans were set in motion to bring this life-saving vaccine to those who needed it most. Ghana, Nigeria, and Burkina Faso were chosen as the first countries to receive the vaccine. For people like Kwame and his daughter Ama, this news brought a glimmer of hope in their ongoing battle against malaria. The logistics of distributing the vaccine were daunting. It required a coordinated effort between local healthcare providers, governments, and international health organizations. But the potential impact was too significant to ignore. Dr. Amina Diallo, a public health official in Burkina Faso, stood before a group of local healthcare workers, explaining the importance of the new vaccine. "This is not just another medicine," she said, her voice filled with passion. "This is our chance to rewrite the story of malaria in our country. Each dose we administer is a step towards a healthier future for our children." The rollout began slowly but steadily. In clinics and hospitals across the selected countries, children lined up to receive their shots. Parents, who had lived in fear of malaria for generations, dared to hope that their children might grow up in a world where the disease was no longer a constant threat. For Kwame and Ama, the vaccine came just in time. As Ama recovered from her bout with malaria, Kwame took her to their local clinic to receive the R21/Matrix-M vaccine. "Will this stop her from getting sick again?" Kwame asked the nurse as she prepared the injection. The nurse smiled gently. "It's not a guarantee," she explained, "but it will give her a much better chance of staying healthy. And with each child we vaccinate, we make our whole community stronger against malaria." As the needle entered Ama's arm, Kwame felt a weight lift from his shoulders. For the first time in years, he allowed himself to imagine a future where he didn't have to fear the coming of the rains and the mosquitoes they brought. Back in Oxford, Sarah and her team were far from resting on their laurels. The success of the R21/Matrix-M vaccine had energized them, spurring them on to even greater endeavors. "We've made a huge step forward," Sarah told her team, "but our work is far from over. There are other strains of malaria out there, other stages in the parasite's lifecycle that we can target. We need to keep pushing, keep innovating." And push they did. In labs around the world, inspired by the success of R21/Matrix-M, researchers redoubled their efforts. They explored new approaches, studied different proteins on the parasite's surface, and looked for ways to make vaccines even more effective. The impact of the R21/Matrix-M vaccine was soon felt across the affected regions. Hospital wards that had once been filled to capacity with malaria patients began to see fewer severe cases. Children who might once have missed school due to recurring bouts of the disease were now able to attend classes regularly. Dr. Diallo, reviewing the latest health statistics for her region, could hardly believe her eyes. "The number of malaria cases has dropped by over 50% in just one year," she announced to her team. "This vaccine is not just saving lives; it's transforming our entire healthcare system." Indeed, as the burden of malaria began to lift, hospitals and clinics found they had more resources to dedicate to other pressing health issues. The ripple effects of the vaccine's success were felt throughout society, from increased productivity as fewer work days were lost to illness, to improved educational outcomes as children spent more time in school. But the fight against malaria was far from over. While the R21/Matrix-M vaccine was a powerful tool, it was not a silver bullet. Mosquito control programs, distribution of bed nets, and other preventive measures remained crucial in the ongoing battle against the disease. Moreover, the parasite that caused malaria was notorious for its ability to adapt and evolve. Scientists knew that they needed to stay one step ahead, continuing to refine and improve their vaccines to maintain their effectiveness. Five years after the initial rollout of the R21/Matrix-M vaccine, Kwame stood proudly at Ama's school graduation ceremony. His daughter, now a healthy teenager, had not suffered a single bout of malaria since receiving the vaccine as a child. As he watched Ama accept her diploma, Kwame's mind wandered back to that fearful night when he had sat outside his home, swatting at mosquitoes and praying for a miracle. The miracle had come, not in the form of divine intervention, but through the dedicated work of scientists like Sarah and her team, and the collaborative efforts of countless individuals around the world. In her lab in Oxford, Sarah Johnson looked at a photo on her desk. It showed her standing with a group of smiling children in Burkina Faso, taken during a recent visit to see the impact of the vaccine firsthand. She picked up the photo, a smile playing on her lips. "We've come so far," she murmured, "but there's still so much to do." And with that, she turned back to her microscope, ready to face the next challenge in the ongoing fight against malaria. For Sarah, Kwame, Ama, and millions of others around the world, the R21/Matrix-M vaccine had turned the tide in humanity's ancient battle against the tiny parasite. It was a reminder of what could be achieved when human ingenuity, scientific rigor, and global cooperation came together to tackle even the most formidable of foes. As the sun set over Oxford and rose over Ghana, the world slept a little easier, knowing that each new day brought them closer to a future free from the scourge of malaria. The mosquito's reign of terror was coming to an end, one vaccine dose at a time. The success of the R21/Matrix-M vaccine had far-reaching implications beyond just the realm of public health. It sparked a renewed interest in tropical disease research, attracting funding and talented scientists to a field that had long been underfunded and overlooked. Governments and philanthropic organizations, seeing the tangible results of their investments, increased their support for similar initiatives targeting other neglected diseases. In universities across the globe, a new generation of students, inspired by the breakthrough, chose to pursue careers in infectious disease research and global health. They saw in Sarah's work a model for how science could make a real, measurable difference in the lives of millions. The vaccine's success also had unexpected economic benefits. As malaria rates dropped, tourism to previously high-risk areas began to increase. Local economies that had long suffered under the shadow of the disease started to flourish. Farmers who had once lost precious workdays to illness found themselves more productive, contributing to improved food security in their regions. But perhaps the most profound impact was on the children. In villages and cities across Africa, a generation was growing up without the constant threat of malaria hanging over them. They attended school more regularly, played outside wit

In the heart of a bustling research lab at Oxford University, Dr. Sarah Johnson peered intently into her microscope. For years, she and her team had been working tirelessly on a project that could change the lives of millions. Their goal? To create a vaccine that could finally put an end to one of humanity's oldest and deadliest foes: malaria. Sarah's journey had begun years earlier when, as a young medical student, she had volunteered in a rural clinic in Burkina Faso. There, she had witnessed firsthand the devastating impact of malaria, particularly on children. The image of a mother cradling her feverish child, helpless against the parasites ravaging the little one's body, had stayed with her ever since. "We're close," Sarah muttered to herself, adjusting the focus on her microscope. "I can feel it." And indeed, they were. After years of painstaking research, countless failures, and glimmers of hope, Sarah and her team had developed a vaccine they called R21/Matrix-M. It was a mouthful of a name, but it held the promise of saving countless lives. Meanwhile, in a small village in Ghana, Kwame sat outside his home, swatting at mosquitoes in the evening air. His young daughter, Ama, lay inside, her small body wracked with fever. Malaria had struck again, as it did every year when the rains came. Kwame had lost his eldest son to the disease three years ago. Now, as he listened to Ama's labored breathing, he prayed for a miracle. Little did he know that halfway across the world, that miracle was taking shape in the form of a tiny vial of vaccine. Back in Oxford, Sarah's team received the news they had been waiting for. The results from their latest clinical trial were in, and they were nothing short of remarkable. The R21/Matrix-M vaccine had shown an efficacy rate of up to 77% in young children who received a booster dose. "This is it!" Sarah exclaimed, her eyes shining with excitement as she shared the news with her team. "We've done it!" But what exactly had they done? How did this tiny vial of liquid manage to outsmart a parasite that had been outwitting humans for millennia? The secret lay in the vaccine's clever design. It targeted a specific protein found on the surface of the malaria parasite called the circumsporozoite protein, or CSP for short. Think of CSP as the parasite's coat – by teaching the body's immune system to recognize and attack this coat, the vaccine effectively stopped the parasite in its tracks before it could cause harm. But the R21/Matrix-M vaccine had another trick up its sleeve. It included a special ingredient called an adjuvant – Matrix-M. This adjuvant worked like a megaphone for the immune system, amplifying the body's response to the vaccine and making it more effective. As news of the vaccine's success spread, it reached the ears of world leaders and health organizations. In boardrooms and government offices, plans were set in motion to bring this life-saving vaccine to those who needed it most. Ghana, Nigeria, and Burkina Faso were chosen as the first countries to receive the vaccine. For people like Kwame and his daughter Ama, this news brought a glimmer of hope in their ongoing battle against malaria. The logistics of distributing the vaccine were daunting. It required a coordinated effort between local healthcare providers, governments, and international health organizations. But the potential impact was too significant to ignore. Dr. Amina Diallo, a public health official in Burkina Faso, stood before a group of local healthcare workers, explaining the importance of the new vaccine. "This is not just another medicine," she said, her voice filled with passion. "This is our chance to rewrite the story of malaria in our country. Each dose we administer is a step towards a healthier future for our children." The rollout began slowly but steadily. In clinics and hospitals across the selected countries, children lined up to receive their shots. Parents, who had lived in fear of malaria for generations, dared to hope that their children might grow up in a world where the disease was no longer a constant threat. For Kwame and Ama, the vaccine came just in time. As Ama recovered from her bout with malaria, Kwame took her to their local clinic to receive the R21/Matrix-M vaccine. "Will this stop her from getting sick again?" Kwame asked the nurse as she prepared the injection. The nurse smiled gently. "It's not a guarantee," she explained, "but it will give her a much better chance of staying healthy. And with each child we vaccinate, we make our whole community stronger against malaria." As the needle entered Ama's arm, Kwame felt a weight lift from his shoulders. For the first time in years, he allowed himself to imagine a future where he didn't have to fear the coming of the rains and the mosquitoes they brought. Back in Oxford, Sarah and her team were far from resting on their laurels. The success of the R21/Matrix-M vaccine had energized them, spurring them on to even greater endeavors. "We've made a huge step forward," Sarah told her team, "but our work is far from over. There are other strains of malaria out there, other stages in the parasite's lifecycle that we can target. We need to keep pushing, keep innovating." And push they did. In labs around the world, inspired by the success of R21/Matrix-M, researchers redoubled their efforts. They explored new approaches, studied different proteins on the parasite's surface, and looked for ways to make vaccines even more effective. The impact of the R21/Matrix-M vaccine was soon felt across the affected regions. Hospital wards that had once been filled to capacity with malaria patients began to see fewer severe cases. Children who might once have missed school due to recurring bouts of the disease were now able to attend classes regularly. Dr. Diallo, reviewing the latest health statistics for her region, could hardly believe her eyes. "The number of malaria cases has dropped by over 50% in just one year," she announced to her team. "This vaccine is not just saving lives; it's transforming our entire healthcare system." Indeed, as the burden of malaria began to lift, hospitals and clinics found they had more resources to dedicate to other pressing health issues. The ripple effects of the vaccine's success were felt throughout society, from increased productivity as fewer work days were lost to illness, to improved educational outcomes as children spent more time in school. But the fight against malaria was far from over. While the R21/Matrix-M vaccine was a powerful tool, it was not a silver bullet. Mosquito control programs, distribution of bed nets, and other preventive measures remained crucial in the ongoing battle against the disease. Moreover, the parasite that caused malaria was notorious for its ability to adapt and evolve. Scientists knew that they needed to stay one step ahead, continuing to refine and improve their vaccines to maintain their effectiveness. Five years after the initial rollout of the R21/Matrix-M vaccine, Kwame stood proudly at Ama's school graduation ceremony. His daughter, now a healthy teenager, had not suffered a single bout of malaria since receiving the vaccine as a child. As he watched Ama accept her diploma, Kwame's mind wandered back to that fearful night when he had sat outside his home, swatting at mosquitoes and praying for a miracle. The miracle had come, not in the form of divine intervention, but through the dedicated work of scientists like Sarah and her team, and the collaborative efforts of countless individuals around the world. In her lab in Oxford, Sarah Johnson looked at a photo on her desk. It showed her standing with a group of smiling children in Burkina Faso, taken during a recent visit to see the impact of the vaccine firsthand. She picked up the photo, a smile playing on her lips. "We've come so far," she murmured, "but there's still so much to do." And with that, she turned back to her microscope, ready to face the next challenge in the ongoing fight against malaria. For Sarah, Kwame, Ama, and millions of others around the world, the R21/Matrix-M vaccine had turned the tide in humanity's ancient battle against the tiny parasite. It was a reminder of what could be achieved when human ingenuity, scientific rigor, and global cooperation came together to tackle even the most formidable of foes. As the sun set over Oxford and rose over Ghana, the world slept a little easier, knowing that each new day brought them closer to a future free from the scourge of malaria. The mosquito's reign of terror was coming to an end, one vaccine dose at a time. The success of the R21/Matrix-M vaccine had far-reaching implications beyond just the realm of public health. It sparked a renewed interest in tropical disease research, attracting funding and talented scientists to a field that had long been underfunded and overlooked. Governments and philanthropic organizations, seeing the tangible results of their investments, increased their support for similar initiatives targeting other neglected diseases. In universities across the globe, a new generation of students, inspired by the breakthrough, chose to pursue careers in infectious disease research and global health. They saw in Sarah's work a model for how science could make a real, measurable difference in the lives of millions. The vaccine's success also had unexpected economic benefits. As malaria rates dropped, tourism to previously high-risk areas began to increase. Local economies that had long suffered under the shadow of the disease started to flourish. Farmers who had once lost precious workdays to illness found themselves more productive, contributing to improved food security in their regions. But perhaps the most profound impact was on the children. In villages and cities across Africa, a generation was growing up without the constant threat of malaria hanging over them. They attended school more regularly, played outside wit

Malaria Vaccine

Rosa Koppelmann ist die Leaderin im Paradigma der gelebten Non-Dualität und nimmt dich in diesem Podcast mit in die grenzenlose Welt des All-Eins-Sein. Denn wenn alles eins ist, ist alles easy.

Kreiere dir in Leichtigkeit und Vertrauen das Leben deiner Träume und steppe in deine Schöpferkraft.

Willkommen in der Welt in der der Kampf und die Anstrengung endet und Frieden und Leichtigkeit dein neues Normal sind.

Rosa Koppelmann ist die Leaderin im Paradigma der gelebten Non-Dualität und nimmt dich in diesem Podcast mit in die grenzenlose Welt des All-Eins-Sein. Denn wenn alles eins ist, ist alles easy. Kreiere dir in Leichtigkeit und Vertrauen das Leben deiner Träume und steppe in deine Schöpferkraft. Willkommen in der Welt in der der Kampf und die Anstrengung endet und Frieden und Leichtigkeit dein neues Normal sind.

Rosa's Room

EU CVC

Arrieritos we are and in the way we'll meet.

Enteratec

faithfulfellowshipministries

Elin Vatnar Nilsen er konditor og forfatter som driver bakebloggen krem.no. Denne sesongen av Kremsnakk har hun fått med seg konditor Bernhard Azinger, og sammen skal de dissekere andre sesong av Bakemesterskapet, som sendes på NRK.  Du vil få analyser, kvalifisert synsing, kunnskap og forklaring på hvorfor det går galt. For galt går det jo!

Elin Vatnar Nilsen er konditor og forfatter som driver bakebloggen krem.no. Denne sesongen av Kremsnakk har hun fått med seg konditor Bernhard Azinger, og sammen skal de dissekere andre sesong av Bakemesterskapet, som sendes på NRK. Du vil få analyser, kvalifisert synsing, kunnskap og forklaring på hvorfor det går galt. For galt går det jo!

KREMSNAKK

Aileen's podcast

山の中に、小さな山小屋がある。
そこで、親父と息子が取り止めのない話をする。

農業のこと、仕事のこと、暮らしのこと。
本、音楽、映画、食べもの、そして「粋か野暮か」。

正解は出さない。
結論も急がない。
ただ、ちゃんと考えて、ちゃんと生きる。

これは、
暇と退屈を悪者にしないためのポッドキャスト。
山小屋から、こんにちは。

山の中に、小さな山小屋がある。 そこで、親父と息子が取り止めのない話をする。 農業のこと、仕事のこと、暮らしのこと。 本、音楽、映画、食べもの、そして「粋か野暮か」。 正解は出さない。 結論も急がない。 ただ、ちゃんと考えて、ちゃんと生きる。 これは、 暇と退屈を悪者にしないためのポッドキャスト。 山小屋から、こんにちは。

山小屋からこんにちは

The Josh Ezekiel Podcast is a space for deep, compassionate conversations about childhood, family, emotional growth, and everything in between. Hosted by Josh Ezekiel, a trainee child psychotherapist with a background in early years education, this podcast invites listeners into the emotional world of children while reflecting honestly on the journey of becoming a more attuned, self-aware adult.

Each episode explores the powerful link between how children develop — socially, emotionally, and psychologically — and how we, as parents, educators, or individuals, can better support that growth. Through stories, real-world insights, and thought-provoking interviews, Josh explores how children learn, feel, and make sense of the world, while also holding space for adults who are healing from their own traumatic childhoods.

With a blend of personal reflection, practical guidance, and conversations with inspiring guests, the podcast moves between the classroom and the therapy room, from parenting moments to inner child healing. It speaks to those raising children today, and to those who are trying to raise themselves with the love and understanding they didn’t receive growing up.

The Josh Ezekiel Podcast is not just about children — it’s about you. How you relate. How you listen. How you grow. It’s a space for honest dialogue, emotional clarity, and transformative connection, grounded in psychology but rooted in real life.

The Josh Ezekiel Podcast is a space for deep, compassionate conversations about childhood, family, emotional growth, and everything in between. Hosted by Josh Ezekiel, a trainee child psychotherapist with a background in early years education, this podcast invites listeners into the emotional world of children while reflecting honestly on the journey of becoming a more attuned, self-aware adult. Each episode explores the powerful link between how children develop — socially, emotionally, and psychologically — and how we, as parents, educators, or individuals, can better support that growth. Through stories, real-world insights, and thought-provoking interviews, Josh explores how children learn, feel, and make sense of the world, while also holding space for adults who are healing from their own traumatic childhoods. With a blend of personal reflection, practical guidance, and conversations with inspiring guests, the podcast moves between the classroom and the therapy room, from parenting moments to inner child healing. It speaks to those raising children today, and to those who are trying to raise themselves with the love and understanding they didn’t receive growing up. The Josh Ezekiel Podcast is not just about children — it’s about you. How you relate. How you listen. How you grow. It’s a space for honest dialogue, emotional clarity, and transformative connection, grounded in psychology but rooted in real life.

The Josh Ezekiel Podcast

Vi er Nittedal er først og fremst en podcast for ansatte i Nittedal kommune. Først og fremst, men ikke bare: Vi er Nittedal er absolutt ikke hemmelig. Kommunikasjonssjef Kristian Westgård, kommunedirektør Adelheid Buschmann Kristiansen og gjester gir deg førstehånds innsikt i aktuelle temaer som Vi i Nittedal kommune er opptatt av.

Vi er Nittedal

People new to the Netherlands share their personal stories about expectations, experiences and dreams for the future

Newcomers

Vanessa Winkel und Timo Düngen machen es normalerweise morgens früh bei Radio Emscher Lippe, ab jetzt dann auch in eurem Podcast. Ungeschnitten und ungefiltert – jeden Freitag. Mit Weisheiten aus ihrem Alltag, Dönekes für zwischendurch und den letzten zwei Gehirnzellen der Woche.

Dat kannste echt 'n andern sagen

El podcast de sasha

Are you peri or postmenopausal? Do you sometimes feel like you’re losing the plot? Would you love to talk about what’s going on with your mental & physical well-being? Or hear from other women who lost the plot and found it again or went on to rewrite themselves a new story? If so, we’ve got just the podcast. 

Wild, Wise & Curious... lets you do the talking. We’re your hosts, Michelle & Lou! We’re not doctors or psychiatrists, but we are perimenopausal women with other skills and we believe there’s a wisdom in sharing all our stories. Back in the old days, it’s how we all learned! It was our own perimenopausal ‘losing the plot’ stories that led us to create this podcast.

In this podcast, we’ll be chatting with women, just like you, who want to share their stories and importantly, the gems they’ve learned along the way. Interested in joining us, please give us a follow and share with your peri meno mates!

* We cover many topics related to perimenopause and beyond, including anxiety, panic attacks and other symptoms associated with this stage in a woman’s life, so please bear this in mind if these topics could be triggering.

Are you peri or postmenopausal? Do you sometimes feel like you’re losing the plot? Would you love to talk about what’s going on with your mental & physical well-being? Or hear from other women who lost the plot and found it again or went on to rewrite themselves a new story? If so, we’ve got just the podcast. Wild, Wise & Curious... lets you do the talking. We’re your hosts, Michelle & Lou! We’re not doctors or psychiatrists, but we are perimenopausal women with other skills and we believe there’s a wisdom in sharing all our stories. Back in the old days, it’s how we all learned! It was our own perimenopausal ‘losing the plot’ stories that led us to create this podcast. In this podcast, we’ll be chatting with women, just like you, who want to share their stories and importantly, the gems they’ve learned along the way. Interested in joining us, please give us a follow and share with your peri meno mates! * We cover many topics related to perimenopause and beyond, including anxiety, panic attacks and other symptoms associated with this stage in a woman’s life, so please bear this in mind if these topics could be triggering.

Are you peri or postmenopausal? Do you sometimes feel like you’re losing the plot? Would you love to talk about what’s going on with your mental &amp; physical well-being? Or hear from other women who lost the plot and found it again or went on to rewrite themselves a new story? If so, we’ve got just the podcast. 

Wild, Wise &amp; Curious... lets you do the talking. We’re your hosts, Michelle &amp; Lou! We’re not doctors or psychiatrists, but we are perimenopausal women with other skills and we believe there’s a wisdom in sharing all our stories. Back in the old days, it’s how we all learned! It was our own perimenopausal ‘losing the plot’ stories that led us to create this podcast.

In this podcast, we’ll be chatting with women, just like you, who want to share their stories and importantly, the gems they’ve learned along the way. Interested in joining us, please give us a follow and share with your peri meno mates!

* We cover many topics related to perimenopause and beyond, including anxiety, panic attacks and other symptoms associated with this stage in a woman’s life, so please bear this in mind if these topics could be triggering.

Wild, Wise & Curious...

Snackisar i Ö-vik är ÖA:s podd där vi snackar om sånt som alla i Ö-vik snackar om.Ansvarig utgivare: Ingvar NäslundKontakt redaktionen: ingvar.naslund@allehanda.seAnnonsförfrågningar: podcast.sales@bonniernews.se.&nbsp;

Snackisar i Ö-vik är ÖA:s podd där vi snackar om sånt som alla i Ö-vik snackar om.Ansvarig utgivare: Ingvar NäslundKontakt redaktionen: ingvar.naslund@allehanda.seAnnonsförfrågningar: podcast.sales@bonniernews.se. 

Snackisar i Ö-vik

Viva mi gente es un programa que, a trav&eacute;s de sus secciones y colaboradores permite estar al tanto de la actualidad y cuenta con los mejores consejos de nuestros expertos: 
Pasamos consulta con nuestra psic&oacute;loga, abogado laboralista, ling&uuml;&iacute;stica, cocinero, investigador etnogr&aacute;fico, seguridad alimentaria...

Es un programa para conocer Canarias y acompa&ntilde;arte en el d&iacute;a a d&iacute;a con Alexis Hern&aacute;ndez al frente de un equipo incombustible: descubre el lado humano de la actualidad con Carolina Armas y lo m&aacute;s pr&aacute;ctico para el d&iacute;a a d&iacute;a con Jorge Miranda.

Viva mi gente, un programa con identidad canaria, de lunes a viernes, de 10 a 11 de la ma&ntilde;ana, en la radio canaria.

Para intervenir en directo, llama al 900 52 57 52 o env&iacute;a un whatsapp al 616 486 754.

Viva mi gente es un programa que, a través de sus secciones y colaboradores permite estar al tanto de la actualidad y cuenta con los mejores consejos de nuestros expertos: Pasamos consulta con nuestra psicóloga, abogado laboralista, lingüística, cocinero, investigador etnográfico, seguridad alimentaria... Es un programa para conocer Canarias y acompañarte en el día a día con Alexis Hernández al frente de un equipo incombustible: descubre el lado humano de la actualidad con Carolina Armas y lo más práctico para el día a día con Jorge Miranda. Viva mi gente, un programa con identidad canaria, de lunes a viernes, de 10 a 11 de la mañana, en la radio canaria. Para intervenir en directo, llama al 900 52 57 52 o envía un whatsapp al 616 486 754.

Viva mi gente es un programa que, a través de sus secciones y colaboradores permite estar al tanto de la actualidad y cuenta con los mejores consejos de nuestros expertos: 
Pasamos consulta con nuestra psicóloga, abogado laboralista, lingüística, cocinero, investigador etnográfico, seguridad alimentaria...

Es un programa para conocer Canarias y acompañarte en el día a día con Alexis Hernández al frente de un equipo incombustible: descubre el lado humano de la actualidad con Carolina Armas y lo más práctico para el día a día con Jorge Miranda.

Viva mi gente, un programa con identidad canaria, de lunes a viernes, de 10 a 11 de la mañana, en la radio canaria.

Para intervenir en directo, llama al 900 52 57 52 o envía un whatsapp al 616 486 754.

VIVA MI GENTE

Il Ciclismo friulano in libertà è la rubrica settimanale che accompagna tutti coloro che amano il ciclismo, declinato in tutte le sue forme. Risultati, commenti, notizie: il mondo delle due ruote a Nord Est raccontato dalla viva voce dei protagonisti, con un occhio di riguardo per i giovani atleti che si affacciano alla ribalta delle competizioni nazionali ed internazionali. Ogni venerdì, su RadioSpazio103, assieme a Francesco Tonizzo.

Il Ciclismo friulano in libertà è la rubrica settimanale che accompagna tutti coloro che amano il ciclismo, declinato in tutte le sue forme.Risultati, commenti, notizie: il mondo delle due ruote a Nord Est raccontato dalla viva voce dei protagonisti, con un occhio di riguardo per i giovani atleti che si affacciano alla ribalta delle competizioni nazionali ed internazionali.Ogni venerdì, su RadioSpazio103, assieme a Francesco Tonizzo.

Il Ciclismo friulano in libertà è la rubrica settimanale che accompagna tutti coloro che amano il ciclismo, declinato in tutte le sue forme. Risultati, commenti, notizie: il mondo delle due ruote a Nord Est raccontato dalla viva voce dei protagonisti, con un occhio di riguardo per i giovani atleti che si affacciano alla ribalta delle competizioni nazionali ed internazionali. Ogni venerdì, su RadioSpazio103, assieme a Francesco Tonizzo.

FREEûlBike

本节目来源于观察者网，陪你聊聊国际大事。ps.打开蜻蜓FM消息提醒，即可第一时间收到节目更新推送捏！ (来自： https://www.qingting.fm/channels/387255/ )

观棋有语

Dive into captivating stories, intriguing interviews, and thought-provoking discussions that keep you hooked from start to finish. This podcast brings you fresh perspectives on topics ranging from culture and creativity to innovation and personal growth. Whether you're looking for inspiration or simply a deep dive into the minds of experts, each episode offers something unique. With insightful guests and engaging storytelling, you're in for an audio experience that sparks curiosity and fuels your imagination. Tune in and explore the world from a different angle, one episode at a time.

Asher Cruz Podcast

My North Bay Now Newscast, providing you the latest news in North Bay Ontario coming live from the My North Bay Now News Room.

My North Bay Now Newsroom

Vancouver is one of the busiest film and television production centres on the planet. But who powers this thriving local industry? The YVR Screen Scene Podcast seeks to answer that question. Award-winning film and television journalist Sabrina Furminger conducts revealing interviews with the actors, filmmakers, and other talented artists who power the Vancouver film and television industry in this eye-opening twice-weekly podcast.

The YVR Screen Scene Podcast

Magazine d'actualitat de la Catalunya Central amb entrevistes polítiques, socials i culturals. L'Hora L escolta les problemàtiques del territori, amb connexions d'actualitat i descobrint el patrimoni, la gastronomia i les festes de les comarques centrals. De dilluns a divendres de 12h a 13h amb Eli Pagán i Sergi Lladó. - Cadena SER Catalunya Central

Migdia Central - Cadena SER Catalunya Central

Мы всегда храним только САМОЕ ВАЖНОЕ - в памяти, в традициях,
в семье… А что такое это «самое важное» с точки зрения нашего времени? Что
нужно хранить, а что просто «мусор», от которого можно избавиться без
сожалений. Слушайте на Яндекс Музыка: https://music.yandex.ru/artist/413028
Band.link: https://band.link/vladimirbrilev

Мы всегда храним только САМОЕ ВАЖНОЕ - в памяти, в традициях, в семье… А что такое это «самое важное» с точки зрения нашего времени? Что нужно хранить, а что просто «мусор», от которого можно избавиться без сожалений. Слушайте на Яндекс Музыка: https://music.yandex.ru/artist/413028 Band.link: https://band.link/vladimirbrilev

Мы всегда храним только САМОЕ ВАЖНОЕ - в памяти, в традициях,
в семье… А что такое это «самое важное» с точки зрения нашего времени? Что
нужно хранить, а что просто «мусор», от которого можно избавиться без
сожалений. Слушайте на Яндекс Музыка: https://music.yandex.ru/artist/413028
Band.link: https://band.link/vladimirbrilev

Семейные ценности

Bei Zurück aufs Pferd gibt´s angstfreies Reiten auf die Ohren. Sarah berichtet von ihren Erfahrungen als Expertin für angstfreies und feines Reiten und über ihre eigenen Erfahrungen mit der Angst im Sattel.
Hier erwarten dich nützliche Impulse, persönliche Geschichten und handfeste Tipps für eine entspannte Zeit im Sattel, um die Zeit mit deinem Pferd wieder in vollen Zügen genießen zu können.

Hier geht´s zu Sarahs kostenloser Facebook-Gruppe: 
👉 https://www.facebook.com/groups/zurueckaufspferd

Bei Zurück aufs Pferd gibt´s angstfreies Reiten auf die Ohren. Sarah berichtet von ihren Erfahrungen als Expertin für angstfreies und feines Reiten und über ihre eigenen Erfahrungen mit der Angst im Sattel. Hier erwarten dich nützliche Impulse, persönliche Geschichten und handfeste Tipps für eine entspannte Zeit im Sattel, um die Zeit mit deinem Pferd wieder in vollen Zügen genießen zu können. Hier geht´s zu Sarahs kostenloser Facebook-Gruppe: 👉 https://www.facebook.com/groups/zurueckaufspferd

Zurück aufs Pferd

Hila Golfiz's podcast

Mohamed Guhaad's podcast

"another podcast about movies..."
'Eedjit Features' is a comedy podcast from Glasgow, Scotland.

The Eedjits (Cairn &amp; Ryan) try to make sense of a movie on a weekly basis with silly tangents and even worse impressions.

"another podcast about movies..." 'Eedjit Features' is a comedy podcast from Glasgow, Scotland. The Eedjits (Cairn & Ryan) try to make sense of a movie on a weekly basis with silly tangents and even worse impressions.

Eedjit Features

Interviews RCDF

Detta är podcasten om Degerfors IF sett från en supporters sida. Vi diskuterar högt och lågt, vi bjuder in gäster, snackar om laget, sågar och hyllar.
Degerfors IF ÄR hela Sveriges lag. Vi är det lilla laget som egentligen inte ska kunna vara på de stora scenerna och dansa, men nu är vi det, och vi är överjävligt stolta!
Nu kör vi, trevlig lyssning!

Detta är podcasten om Degerfors IF sett från en supporters sida. Vi diskuterar högt och lågt, vi bjuder in gäster, snackar om laget, sågar och hyllar. Degerfors IF ÄR hela Sveriges lag. Vi är det lilla laget som egentligen inte ska kunna vara på de stora scenerna och dansa, men nu är vi det, och vi är överjävligt stolta! Nu kör vi, trevlig lyssning!

Blås av skiten

LE FLASH INFO BEAUNE - K6FM

Duncan njeru podcast

פודקאסט על הפלאים והאימה שבספרות, עם חן מלול

ספריית בבל

Подкаст посвящен исследованиям жанра хоррор. Разбираем фильмы, обсуждаем теории и факты, отвратительно шутим и получаем удовольствие.Наш подкаст преимущественно в формате видео, так что иногда будет полезно его смотреть на видео платформах

Подкаст посвящен исследованиям жанра хоррор. Разбираем фильмы, обсуждаем теории и факты, отвратительно шутим и получаем удовольствие.Наш подкаст преимущественно в формате видео, так что иногда будет полезно его смотреть на видео платформах

Ууу Подкаст

Tune into the Extreme®️ Daily Podcast with Vida Macura Maglica!
 We're here to deliver fresh, engaging, and vibrant content in multiple languages—Slovenian, English, Serbian, Croatian, and Italian.
 With us, you’ll never feel bored! Each episode is an opportunity to learn something new because we believe that growth is a lifelong journey for everyone.
 Join our supportive community and gain access to a variety of FREE resources, including:
• Guided workouts
• Healthy recipes
• Podcasts
• Discounts in our store (available in our Extreme Training® App)
• Direct support from Vida
Simply download our Extreme Training®️ app: <a href="http://onelink.to/extremetraining">http://onelink.to/extremetraining</a>
 With love, Vida

Tune into the Extreme®️ Daily Podcast with Vida Macura Maglica! We're here to deliver fresh, engaging, and vibrant content in multiple languages—Slovenian, English, Serbian, Croatian, and Italian. With us, you’ll never feel bored! Each episode is an opportunity to learn something new because we believe that growth is a lifelong journey for everyone. Join our supportive community and gain access to a variety of FREE resources, including: • Guided workouts • Healthy recipes • Podcasts • Discounts in our store (available in our Extreme Training® App) • Direct support from Vida Simply download our Extreme Training®️ app: http://onelink.to/extremetraining With love, Vida

Tune into the Extreme®️ Daily Podcast with Vida Macura Maglica!
 We're here to deliver fresh, engaging, and vibrant content in multiple languages—Slovenian, English, Serbian, Croatian, and Italian.
 With us, you’ll never feel bored! Each episode is an opportunity to learn something new because we believe that growth is a lifelong journey for everyone.
 Join our supportive community and gain access to a variety of FREE resources, including:
• Guided workouts
• Healthy recipes
• Podcasts
• Discounts in our store (available in our Extreme Training® App)
• Direct support from Vida
Simply download our Extreme Training®️ app: <a href="http://onelink.to/extremetraining" rel="noopener noreferrer">http://onelink.to/extremetraining</a>
 With love, Vida

PODCASTS EXTREME® Daily with Vida Macura Maglica - Extreme Training®

Nah dran an den Menschen, Orten und Themen, die Schalksmühle bewegen! In kurzen, unterhaltsamen Folgen nimmt dich die UWG mit auf eine Reise durch unsere Gemeinde. Von Kultur über Vereinsleben bis zur lokalen Wirtschaft – wir beleuchten, was Schalksmühle ausmacht. Keine Wahlversprechen, sondern echte Einblicke und konkrete Ideen für einen lebenswerten Ort. Was bewegt dich? Schreib uns deine Themenvorschläge! Ein Podcast von Bürgern für Bürger – informativ, herzlich und immer mit Blick für das Besondere unserer Gemeinde.

"Mittendrin in Schalksmühle" - dein Podcast

Summative Assessment 1

Welcome to "Kabbalah 101: Quick Insights," your go-to podcast for understanding the esoteric teachings of Kabbalah in bite-sized episodes. Whether you're a curious beginner or a seasoned practitioner, this podcast aims to provide you with easily digestible insights into the complex world of Kabbalistic thought.

What sets us apart? Each episode focuses on a single concept, symbol, or teaching from Kabbalah, distilling it into an engaging and easily understandable format. In just a few minutes, you'll walk away with a new piece of mystical wisdom that you can apply to your everyday life.

Produced by Daniel Aharonoff

Welcome to "Kabbalah 101: Quick Insights," your go-to podcast for understanding the esoteric teachings of Kabbalah in bite-sized episodes. Whether you're a curious beginner or a seasoned practitioner, this podcast aims to provide you with easily digestible insights into the complex world of Kabbalistic thought. What sets us apart? Each episode focuses on a single concept, symbol, or teaching from Kabbalah, distilling it into an engaging and easily understandable format. In just a few minutes, you'll walk away with a new piece of mystical wisdom that you can apply to your everyday life. Produced by Daniel Aharonoff

Kabbalah 101: Quick Insights

Laupäeva Hommiku Poolik

The Naked Scientists are a media-savvy group of physicians and researchers from Cambridge University who use radio, live lectures, and the Internet to strip science down to its bare essentials, and promote it to the general public. Their award winning BBC weekly radio programme, The Naked Scientists, reaches a potential audience of 6 million listeners across the east of England, and also has an international following on the web.

Naked Scientists

Hun l&aelig;ste Hemingway i f&aelig;ngslet. Han har delt tanker med Tove Ditlevsen over en joint. Hun ser sk&oslash;nheden i Helle Helles skrabede stil. Han har taget LSD med S&oslash;ren Kierkegaard og hans samlede v&aelig;rker. Hun elsker blod og mord p&aring; papir. 
For mange er litteratur noget finkulturelt, for andre en eventyrlig flugt fra dagligdagen og ind i en anden verden. For Sydhavnens L&aelig;seklub er b&oslash;gerne en d&oslash;r&aring;bner til refleksion over levede liv, der i denne podcastserie f&oslash;rer til n&aelig;re og st&aelig;rke personlige beretninger, som b&aring;de rummer stof til eftertanke og g&aring;r lige i hjertet p&aring; lytteren.
Betty, Allan, Fie, Banjo og Jane har v&aelig;ret hjeml&oslash;se og boet p&aring; gaden. De har k&aelig;mpet med vold og misbrug. De har gr&aelig;dt, r&aring;bt og skreget. Men de har ogs&aring; l&aelig;st mere end de fleste, og de har m&oslash;dt historier, der b&aelig;rer smilet i sig. Som tr&oslash;ster og giver h&aring;b. 
Tag med i Sydhavnens L&aelig;seklub sammen med litteraturredakt&oslash;r Marcus Aggersbjerg og fem us&aelig;dvanlige mennesker, der har pr&oslash;vet lidt af hvert &ndash; og som ikke er bange for at dele ud af deres h&aring;rdt optjente klogskab fra fortovskanten.
Premiere 12. april 2025

Hun læste Hemingway i fængslet. Han har delt tanker med Tove Ditlevsen over en joint. Hun ser skønheden i Helle Helles skrabede stil. Han har taget LSD med Søren Kierkegaard og hans samlede værker. Hun elsker blod og mord på papir. For mange er litteratur noget finkulturelt, for andre en eventyrlig flugt fra dagligdagen og ind i en anden verden. For Sydhavnens Læseklub er bøgerne en døråbner til refleksion over levede liv, der i denne podcastserie fører til nære og stærke personlige beretninger, som både rummer stof til eftertanke og går lige i hjertet på lytteren. Betty, Allan, Fie, Banjo og Jane har været hjemløse og boet på gaden. De har kæmpet med vold og misbrug. De har grædt, råbt og skreget. Men de har også læst mere end de fleste, og de har mødt historier, der bærer smilet i sig. Som trøster og giver håb. Tag med i Sydhavnens Læseklub sammen med litteraturredaktør Marcus Aggersbjerg og fem usædvanlige mennesker, der har prøvet lidt af hvert – og som ikke er bange for at dele ud af deres hårdt optjente klogskab fra fortovskanten. Premiere 12. april 2025

Hun læste Hemingway i fængslet. Han har delt tanker med Tove Ditlevsen over en joint. Hun ser skønheden i Helle Helles skrabede stil. Han har taget LSD med Søren Kierkegaard og hans samlede værker. Hun elsker blod og mord på papir. 
For mange er litteratur noget finkulturelt, for andre en eventyrlig flugt fra dagligdagen og ind i en anden verden. For Sydhavnens Læseklub er bøgerne en døråbner til refleksion over levede liv, der i denne podcastserie fører til nære og stærke personlige beretninger, som både rummer stof til eftertanke og går lige i hjertet på lytteren.
Betty, Allan, Fie, Banjo og Jane har været hjemløse og boet på gaden. De har kæmpet med vold og misbrug. De har grædt, råbt og skreget. Men de har også læst mere end de fleste, og de har mødt historier, der bærer smilet i sig. Som trøster og giver håb. 
Tag med i Sydhavnens Læseklub sammen med litteraturredaktør Marcus Aggersbjerg og fem usædvanlige mennesker, der har prøvet lidt af hvert – og som ikke er bange for at dele ud af deres hårdt optjente klogskab fra fortovskanten.
Premiere 12. april 2025

Top Podcasts / Page 29080